Evidence map›Paper›PMID 36063627›Full record

ArticleJournal of psychosomatic research2022

The effects of antidepressants on depressive symptoms in manifest Huntington's disease.

Amy C Ogilvie, Ryan M Carnahan, Elizabeth A Chrischilles, Jordan L Schultz

Open access · greenAbstract read
In one paragraph

Article in Journal of psychosomatic research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Sertraline treatment prevents motor dysfunction in a Huntington's disease mouse model and functional decline in patients.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
  4. Review
  5. The pathobiology of depression in Huntington's disease: an unresolved puzzle.Journal of neural transmission (Vienna, Austria : 1996) · 2024
    Review
  6. Pathomechanisms of behavioral abnormalities in Huntington disease: an update.Journal of neural transmission (Vienna, Austria : 1996) · 2024
    Review
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Amy C OgilvieDepartment of Epidemiology, The College of Public Health at the University of Iowa, United States of America; Department of Psychiatry, The Carver College of Medicine at the University of Iowa, United States of America. Electronic address: Amy-ostrem@uiowa.edu.
Ryan M CarnahanDepartment of Epidemiology, The College of Public Health at the University of Iowa, United States of America.
Elizabeth A ChrischillesDepartment of Epidemiology, The College of Public Health at the University of Iowa, United States of America.
Jordan L SchultzDepartment of Psychiatry, The Carver College of Medicine at the University of Iowa, United States of America; Department of Neurology, The Carver College of Medicine at the University of Iowa, United States of America; Division of Pharmacy Practice and Sciences, The College of Pharmacy at the University of Iowa, United States of America.
University of Iowa · USAmerican Association of Colleges of Pharmacy · US

Funding

Investigating Autonomic Dysfunction as an Early Pathologic Feature of Huntington’s DiseaseK23NS117736 · NINDS · UNIVERSITY OF IOWA · PI SCHULTZ, JORDAN · 2021 to 2025
$895k
NINDS NIH HHS K23 NS117736
6 · The paper itself

Abstract

objectiveCurrently there is little evidence to guide the treatment of depression in Huntington's disease (HD). The primary objective was to determine the effectiveness of antidepressant medications on lowering depressive symptom scores in patients with manifest HD. The secondary objective was to determine the effect of antidepressant use on measures of disease progression.

methodsAfter retrospectively identifying motor-manifest HD participants with at least borderline depressive symptoms from the Enroll-HD database, 86 new users of antidepressant medication were exact matched with non-users on depression score, and matched on propensity scores developed using age, sex, CAG repeat length, anxiety scores, and disease progression measures. Linear mixed effect models were used to assess the change in depression scores, anxiety scores, and disease progression measures based on antidepressant use between two visits approximately one-year apart.

resultsThere was no significant difference in the change in depression score between antidepressant users and non-users (p = 0.46). There were also no significant differences in the change in total motor score (p = 0.88), total functional capacity score (p = 0.16), number correct on the symbol digit modality test (p = 0.49), or anxiety score (p = 0.68).

conclusionsInitiation of antidepressant medication was not associated with a greater reduction in depressive symptoms or changes in other symptoms when compared to non-use. The findings of this study support further research on the effectiveness of antidepressants in Huntington's disease patients. Clinical trials or studies with a larger sample of new antidepressant users should be used to assess the causal effects of antidepressant medications on depressive symptoms.

Indexed as

Huntington DiseaseAntidepressive AgentsDepressionDisease ProgressionHumansRetrospective StudiesAntidepressive AgentsAntidepressantsDepressionHuntington's disease

Identifiers

PMID36063627
PMCPMC9951204
OpenAlexW4293523183

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.